{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:22Z","timestamp":1793176822513,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T21:07:46Z","timestamp":1705180066000},"page":"514-522.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib"],"prefix":"10.1016","volume":"22","author":[{"given":"Martina","family":"Catalano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6008-0266","authenticated-orcid":false,"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.01.006_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2024.01.006_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0003","unstructured":"Memorial Sloan-Kettering Cancer Center (MSKCC\/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)\u2014MDCalc. Available at: https:\/\/www.mdcalc.com\/memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc."},{"key":"10.1016\/j.clgc.2024.01.006_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v13.i1.1","article-title":"Update on the treatment of metastatic renal cell carcinoma","volume":"13","author":"Medina L\u00f3pez","year":"2022","journal-title":"World J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.01.006_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0007","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.01.006_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2020.38.6_suppl.609","article-title":"Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"38","author":"Tannir","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.01.006_bib0010","unstructured":"eUpdate \u2013 Renal Cell Carcinoma Treatment Recommendations | ESMO [Internet]. Available at: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renal-cell-carcinoma-treatment-recommendations-4."},{"key":"10.1016\/j.clgc.2024.01.006_bib0011","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clgc.2024.01.006_bib0012","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0013","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/sj.bjc.6600768","article-title":"Metastatic renal carcinoma comprehensive prognostic system","volume":"88","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2024.01.006_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbcan.2016.12.001","article-title":"Brain metastasis: unique challenges and open opportunities","volume":"1867","author":"Lowery","year":"2017","journal-title":"Biochim Biophysica Acta Rev Cancer"},{"key":"10.1016\/j.clgc.2024.01.006_bib0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.29271\/jcpsp.2020.06.590","article-title":"Prognostic importance of metastatic site in intermediate-risk group metastatic renal cell cancer treated with tyrosine kinase inhibitors","volume":"30","author":"Karacin","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.clgc.2024.01.006_bib0016","unstructured":"Common terminology criteria for adverse events (CTCAE) | protocol development | CTEP [Internet]. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"10.1016\/j.clgc.2024.01.006_bib0017","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/cancers14030644","article-title":"Combination of anti-angiogenics and checkpoint inhibitors for renal cell carcinoma: is the whole greater than the sum of its parts?","volume":"14","author":"Jonasch","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2024.01.006_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.euo.2019.06.018","article-title":"Metastatic renal cell carcinoma rapidly progressive to sunitinib: what to do next?","volume":"4","author":"Bersanelli","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0019","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0020","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.01.006_bib0021","doi-asserted-by":"crossref","first-page":"661.e7","DOI":"10.1016\/j.urolonc.2017.06.060","article-title":"Metastatic renal cell carcinoma: patterns and predictors of metastases\u2014a contemporary population-based series","volume":"35","author":"Chandrasekar","year":"2017","journal-title":"Urol Oncol Semin Orig Investigat"},{"key":"10.1016\/j.clgc.2024.01.006_bib0022","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.clgc.2013.04.022","article-title":"Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center","volume":"11","author":"Grassi","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.01.006_bib0023","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bju.13185","article-title":"Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases","volume":"117","author":"Kalra","year":"2016","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.clgc.2024.01.006_bib0024","doi-asserted-by":"crossref","first-page":"e134564","DOI":"10.1172\/jci.insight.134564","article-title":"Pancreatic tropism of metastatic renal cell carcinoma","volume":"5","author":"Singla","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.clgc.2024.01.006_bib0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0026","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.01.006_bib0027","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/biomedicines10102444","article-title":"Long-term response to tyrosine kinase inhibitors for metastatic renal cell carcinoma","volume":"10","author":"Catalano","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clgc.2024.01.006_bib0028","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2024.01.006_bib0029","doi-asserted-by":"crossref","first-page":"e034626","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.clgc.2024.01.006_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.urology.2021.08.023","article-title":"A systematic review and meta-analysis of dual therapy in patients with advanced renal cell carcinoma of favourable risk","volume":"157","author":"Kartolo","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2024.01.006_bib0031","article-title":"Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis","volume":"13","author":"Cattrini","year":"2021","journal-title":"Therap Adv Urol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.739263","article-title":"Balancing the risk-benefit ratio of immune checkpoint inhibitor and anti-VEGF combination therapy in renal cell carcinoma: a systematic review and meta-analysis","volume":"11","author":"Tao","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.006_bib0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12032-020-1340-7","article-title":"To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitoris necessary in the treatment of advanced or metastatic renal cell carcinoma","volume":"37","author":"Sun","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0034","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s12094-020-02292-z","article-title":"Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis","volume":"22","author":"Buti","year":"2020","journal-title":"Clin Translat Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0035","doi-asserted-by":"crossref","first-page":"LBA4501","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Rini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0036","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2023.41.16_suppl.4502","article-title":"Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"41","author":"Motzer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.01.006_bib0037","doi-asserted-by":"crossref","first-page":"VIII724","DOI":"10.1093\/annonc\/mdy424.037","article-title":"Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Rini","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.006_bib0038","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","article-title":"A systematic review and meta analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma","volume":"71","author":"Fern\u00e1ndez-Pello","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.006_bib0039","doi-asserted-by":"crossref","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2024.01.006_bib0040","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.01.006_bib0041","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.01.006_bib0042","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.01.006_bib0043","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.3389\/fonc.2022.918413","article-title":"Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors","volume":"12","author":"Roviello","year":"2022","journal-title":"Front Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:30:15Z","timestamp":1793176215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767324000077"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}